This trial is testing a new cancer drug, given in combination with other anti-cancer agents, to people with cancer that has come back or did not respond to other treatments.
3 Primary · 18 Secondary · Reporting Duration: Cycle 1 (5 weeks in total) on Day 1 of Week 1, 2 and 3, and Cycle 2 (3 weeks in total) on Day 1 of Week 1
Experimental Treatment
117 Total Participants · 3 Treatment Groups
Primary Treatment: AZD4573 · No Placebo Group · Phase 1 & 2
Age 18 - 130 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: